Business Context and Reporting Period
Company: Microbot Medical Inc. (MBOT)
Filing Type: Form 8-K (Current Report)
Date of Report: April 1, 2025
Reporting Period: Event-based disclosure regarding clinical trial data presentation and regulatory expectations.
Key Financial Metrics
This filing is a current report regarding material events and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
- Clinical Data Presentation: Data from the ACCESS-PVI trial will be presented via a podium presentation by Dr. Francois Cornelis on April 2, 2025, at Memorial Sloan Kettering Cancer Center.
- Regulatory Timeline: The Company reaffirmed its expectation that the FDA will issue a decision regarding the 510(K) clearance of the LIBERTY® device during the second quarter of 2025.
Guidance, Outlook, and Risks
Outlook: Management expects a regulatory decision on the LIBERTY® 510(K) clearance in Q2 2025.
Regulatory FD Disclosure: The information provided is furnished under Item 7.01 (Regulation FD) and is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Risks: The filing does not explicitly detail new risks, though the timeline for FDA clearance remains an expectation rather than a guarantee.
Investor Verification Checklist
- Verify the date and time of the ACCESS-PVI trial podium presentation (April 2, 2025, 11:33 am CT).
- Confirm the specific details of the LIBERTY® 510(K) clearance timeline in the referenced press release (Exhibit 99.1).
- Monitor subsequent filings for the actual FDA decision outcome in Q2 2025.
- Review the full text of the press release (Exhibit 99.1) for any additional clinical data points not summarized in the 8-K.